Lactate dehydrogenase (LDH) levels to predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Subgroup analysis of the randomized BEBYP study

被引：0
|
作者：
Marmorino, Federica
Cremolini, Chiara
Loupakis, Fotios
Barbara, Cecilia
Dargenio, Francesco
Miraglio, Emanuela
Masi, Gianluca
Salvatore, Lisa
Marcucci, Lorenzo
Antonuzzo, Lorenzo
Chiara, Silvana
Banzi, Chiara
Schirripa, Marta
Amoroso, Domenico
Bonetti, Andrea
Martignetti, Angelo
Paris, Myriam
Boni, Luca
Tomcikova, Daniela
Falcone, Alfredo
机构：
[1] Azienda Osped Univ Pisana, UO Oncol Med 2, Ist Toscano Tumori, Pisa, Italy
[2] Azienda Osped Univ Pisana, Ist Toscano Tumori, Pisa, Italy
[3] Ist Toscano Tumori, Pisa, Italy
[4] Osped Civile Livorno, Dept Med Oncol, Livorno, Italy
[5] AUSL 6 Livorno, Dipartimento Oncol, Piombino, Italy
[6] S Croce Gen Hosp, Dept Oncol, Cuneo, Italy
[7] UO Oncol Med Azienda Toscana Nord Ovest, Dipartimento Oncol, Pontedera, Italy
[8] Azienda Osped Univ Careggi, Florence, Italy
[9] Natl Inst Canc Res, Genoa, Italy
[10] Arcispedale Santa Maria Nuova, IRCCS, Reggio Emilia, Italy
[11] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA, Italy
[12] Osped Versilia, Lido Di Camaiore, Italy
[13] Dept Med Oncol, Legnago, Italy
[14] Unita Operat Oncol Med, Siena, Italy
[15] Osped Inferm Biella, SOC Oncol, Biella, Italy
[16] Ist Toscano Tumori, AOU Careggi, Clin Trial Coordinating Ctr, Florence, Italy
[17] Fdn Sandro Pitigliani, Peato, Italy
[18] UO Oncol Med 2 Univ, Pisa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e15127
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15127
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study
    Marmorino, F.
    Cremolini, C.
    Loupakis, F.
    Salvatore, L.
    Masi, G.
    Barbara, C.
    Dargenio, F.
    Miraglio, E.
    Ginocchi, L.
    Antonuzzo, L.
    Moretto, R.
    Schirripa, M.
    Chiara, S.
    Banzi, C.
    Amoroso, D.
    Bonetti, A.
    Martignetti, A.
    Paris, M.
    Boni, L.
    Tomcikova, D.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study
    Marmorino, F.
    Cremolini, C.
    Loupakis, F.
    Antoniotti, C.
    Barbara, C.
    Dargenio, F.
    Miraglio, E.
    Masi, G.
    Salvatore, L.
    Schirripa, M.
    Borelli, B.
    Marcucci, L.
    Antonuzzo, L.
    Chiara, S.
    Banzi, C.
    Amoroso, D.
    Bonetti, A.
    Martignetti, A.
    Paris, M.
    Boni, L.
    Tomcikova, D.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2016, 27 : 103 - 103
  • [3] Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Traslational analyses from the phase III BEBYP trial
    Antoniotti, Carlotta
    Loupakis, Fotios
    Cremolini, Chiara
    Bocci, Guido
    Fioravanti, Anna
    Masi, Gianluca
    Salvatore, Lisa
    Marmorino, Federica
    Orlandi, Paola
    Schirripa, Marta
    Bergamo, Francesca
    Zoratto, Federica
    Di Desidero, Teresa
    Canu, Bastianina
    Danesi, Romano
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial
    Cremolini, Chiara
    Loupakis, Fotios
    Bocci, Guido
    Fioravanti, Anna
    Masi, Gianluca
    Salvatore, Lisa
    Marmorino, Federica
    Orlandi, Paola
    Schirripa, Marta
    Di Desidero, Teresa
    Antoniotti, Carlotta
    Canu, Bastianina
    Danesi, Romano
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [5] Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer
    Federica Marmorino
    Lisa Salvatore
    Cecilia Barbara
    Giacomo Allegrini
    Lorenzo Antonuzzo
    Gianluca Masi
    Fotios Loupakis
    Beatrice Borelli
    Silvana Chiara
    Maria Chiara Banzi
    Emanuela Miraglio
    Domenico Amoroso
    Francesco Dargenio
    Andrea Bonetti
    Angelo Martignetti
    Myriam Paris
    Daniela Tomcikova
    Luca Boni
    Alfredo Falcone
    Chiara Cremolini
    British Journal of Cancer, 2017, 116 : 318 - 323
  • [6] Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer
    Marmorino, Federica
    Salvatore, Lisa
    Barbara, Cecilia
    Allegrini, Giacomo
    Antonuzzo, Lorenzo
    Masi, Gianluca
    Loupakis, Fotios
    Borelli, Beatrice
    Chiara, Silvana
    Banzi, Maria Chiara
    Miraglio, Emanuela
    Amoroso, Domenico
    Dargenio, Francesco
    Bonetti, Andrea
    Martignetti, Angelo
    Paris, Myriam
    Tomcikova, Daniela
    Boni, Luca
    Falcone, Alfredo
    Cremolini, Chiara
    BRITISH JOURNAL OF CANCER, 2017, 116 (03) : 318 - 323
  • [7] 2nd line bevacizumab(BEV) continuation chemotherapy(Cx) beyond early progression for metastatic colorectal cancer(mCRC)
    Komoda, Masato
    Yamamoto, Shun
    Kawakami, Takeshi
    Mitani, Seiichiro
    Tsuji, Yasushi
    Izawa, Naoki
    Kawakami, Kentaro
    Yamamoto, Yoshiyuki
    Makiyama, Akitaka
    Yamazaki, Kentaro
    Masuishi, Toshiki
    Esaki, Taito
    Tsuda, Takashi
    Okuda, Hiroyuki
    Moriwaki, Toshikazu
    Boku, Narikazu
    ANNALS OF ONCOLOGY, 2019, 30 : 100 - 100
  • [8] Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial
    Masi, G.
    Salyatore, L.
    Boni, L.
    Loupakis, F.
    Cremolini, C.
    Fornaro, L.
    Schirripa, M.
    Cupini, S.
    Barbara, C.
    Safina, V.
    Granetto, C.
    Fea, E.
    Antonuzzo, L.
    Boni, C.
    Allegrini, G.
    Chiara, S.
    Amoroso, D.
    Bonetti, A.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2015, 26 (04) : 724 - 730
  • [9] An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (BEV) in metastatic colorectal cancer (MCRC)
    Hecht, J.
    Chiciac, T.
    Mitchell, E.
    Stella, P.
    Cohn, A.
    McCollum, D.
    Saleh, M.
    Marshall, A.
    Shahin, S.
    Deeter, R.
    ANNALS OF ONCOLOGY, 2007, 18 : VII21 - VII22
  • [10] Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).
    Arnold, Dirk
    Andre, Thierry
    Bennouna, Jaafar
    Sastre, Javier
    Osterlund, Pia J.
    Greil, Richard
    Van Cutsem, Eric
    Von Moos, Roger
    Reyes-Rivera, Irmarie
    Bendahmane, Belguendouz
    Kubicka, Stefan
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345